DE69402703D1 - 3- (INDOL-3-YL) PROPENIC ACID DERIVATIVES USEFUL AS NMDA ANTAGONISTS - Google Patents

3- (INDOL-3-YL) PROPENIC ACID DERIVATIVES USEFUL AS NMDA ANTAGONISTS

Info

Publication number
DE69402703D1
DE69402703D1 DE69402703T DE69402703T DE69402703D1 DE 69402703 D1 DE69402703 D1 DE 69402703D1 DE 69402703 T DE69402703 T DE 69402703T DE 69402703 T DE69402703 T DE 69402703T DE 69402703 D1 DE69402703 D1 DE 69402703D1
Authority
DE
Germany
Prior art keywords
acid derivatives
indol
derivatives useful
nmda antagonists
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69402703T
Other languages
German (de)
Other versions
DE69402703T2 (en
Inventor
Francesco Salituro
Bruce Baron
Boyd Harrison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of DE69402703D1 publication Critical patent/DE69402703D1/en
Application granted granted Critical
Publication of DE69402703T2 publication Critical patent/DE69402703T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound of formula (I), wherein Z is hydrogen, -CH3, or -C2H5; X and Y are represented by -OH, a physiologically acceptable ester, or a physiologically acceptable amide; R is represented by from 1 to 3 substituents independently chosen from the group: hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, -CF3, or -OCF3; R1 is represented by from 1 to 3 substituents independently chosen from the group: hydrogen, amino, C1-4 alkyl, C1-4 alkoxy, halogen, -CF3, or -OCF3; and pharmaceutically acceptable addition salts thereof. These 3-indolyl-3-yl-propenoic acid derivatives are useful as NMDA antagonist.
DE69402703T 1993-05-27 1994-05-02 3- (INDOL-3-YL) PROPENIC ACID DERIVATIVES USEFUL AS NMDA ANTAGONISTS Expired - Lifetime DE69402703T2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6836793A 1993-05-27 1993-05-27
US13932393A 1993-10-19 1993-10-19
US19081494A 1994-02-02 1994-02-02
PCT/US1994/005023 WO1994027964A1 (en) 1993-05-27 1994-05-02 3-(indol-3-yl) propenoic acid derivatives and as nmda antagonists

Publications (2)

Publication Number Publication Date
DE69402703D1 true DE69402703D1 (en) 1997-05-22
DE69402703T2 DE69402703T2 (en) 1997-11-27

Family

ID=27371322

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69402703T Expired - Lifetime DE69402703T2 (en) 1993-05-27 1994-05-02 3- (INDOL-3-YL) PROPENIC ACID DERIVATIVES USEFUL AS NMDA ANTAGONISTS

Country Status (17)

Country Link
EP (1) EP0701551B1 (en)
JP (1) JP3334805B2 (en)
KR (1) KR100314482B1 (en)
CN (1) CN1051302C (en)
AT (1) ATE151750T1 (en)
AU (1) AU681402B2 (en)
CA (1) CA2161768C (en)
DE (1) DE69402703T2 (en)
DK (1) DK0701551T3 (en)
ES (1) ES2103590T3 (en)
FI (1) FI955604A (en)
GR (1) GR3023973T3 (en)
HU (1) HU216633B (en)
IL (1) IL109744A (en)
NO (1) NO306021B1 (en)
TW (1) TW262467B (en)
WO (1) WO1994027964A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5563157B1 (en) 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
KR20000048715A (en) * 1996-09-30 2000-07-25 게리 디. 스트리트, 스티븐 엘. 네스비트 Nmda (n-methyl-d-aspartate) antagonists
CN101770315B (en) 2009-01-05 2012-05-23 鸿富锦精密工业(深圳)有限公司 Touch electronic device with sliding control function and sliding control method thereof
CN113419009B (en) * 2021-06-29 2023-02-07 国家烟草质量监督检验中心 Liquid chromatography tandem mass spectrometry determination method for fluensulfone metabolite
CN113419008B (en) * 2021-06-29 2023-02-07 国家烟草质量监督检验中心 Synthetic phase chromatography tandem mass spectrometry determination method for fluensulfone metabolite

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
JP6788745B2 (en) * 2017-07-25 2020-11-25 株式会社日立ハイテク Automatic analyzer

Also Published As

Publication number Publication date
TW262467B (en) 1995-11-11
JPH09508615A (en) 1997-09-02
KR100314482B1 (en) 2002-02-28
NO954769L (en) 1996-01-25
HU9503367D0 (en) 1996-01-29
HU216633B (en) 1999-07-28
EP0701551A1 (en) 1996-03-20
AU6784394A (en) 1994-12-20
KR960702438A (en) 1996-04-27
IL109744A0 (en) 1994-08-26
DK0701551T3 (en) 1997-10-20
NO954769D0 (en) 1995-11-24
FI955604A0 (en) 1995-11-21
ES2103590T3 (en) 1997-09-16
GR3023973T3 (en) 1997-10-31
NO306021B1 (en) 1999-09-06
AU681402B2 (en) 1997-08-28
IL109744A (en) 1999-06-20
CA2161768C (en) 1998-08-18
EP0701551B1 (en) 1997-04-16
FI955604A (en) 1995-11-21
JP3334805B2 (en) 2002-10-15
WO1994027964A1 (en) 1994-12-08
CA2161768A1 (en) 1994-12-08
ATE151750T1 (en) 1997-05-15
HUT74620A (en) 1997-01-28
CN1124484A (en) 1996-06-12
DE69402703T2 (en) 1997-11-27
CN1051302C (en) 2000-04-12

Similar Documents

Publication Publication Date Title
LV11617A (en) Morpholine and thiomorpholine with tachykinin receptor antagonist ipasibam
DE69027562D1 (en) Xanthine compounds
AU641952B2 (en) Substituted N-(imidazolyl)alkyl alanine derivatives
IE811085L (en) Pyridoxine derivatives
DK0902018T3 (en) 2- (arylpheny) amino-imidazoline derivatives
DE69402703D1 (en) 3- (INDOL-3-YL) PROPENIC ACID DERIVATIVES USEFUL AS NMDA ANTAGONISTS
ATE170851T1 (en) GUANIDINOTHIAZOLE DERIVATIVES AND THEIR USE AS H2 RECEPTOR ANTAGONISTS
TW334428B (en) Novel benzodiazepine derivatives
EA200101050A1 (en) SUBSTITUTED BENZOLACTAM COMPOUNDS
NZ291855A (en) Bridged azabicyclo-piperazin-1-yl-2-phenyl-butan-1-one derivatives as 5-ht1a antagonists
CA2009542A1 (en) Cyclic guanidines as calcium antagonists
ATE264320T1 (en) 5-AMINOALKYL AND 5-AMINOCARBONYL SUBSTITUTED INDOLES
YU38498A (en) 2-(arylphenyl)amino-imidazoline derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS INC. (N.D.GES.D. STAATES PENNSYLVANIA), GR

8327 Change in the person/name/address of the patent owner

Owner name: AVENTISUB II INC., GREENVILLE, DEL., US